Informed Bayesian survival analysis

12/15/2021
by   František Bartoš, et al.
0

We overview Bayesian estimation, hypothesis testing, and model-averaging and illustrate how they benefit parametric survival analysis. We contrast the Bayesian framework to the currently dominant frequentist approach and highlight advantages, such as seamless incorporation of historical data, continuous monitoring of evidence, and incorporating uncertainty about the true data generating process. We illustrate the application of the Bayesian approaches on an example data set from a colon cancer trial. We compare the Bayesian parametric survival analysis and frequentist models with AIC/BIC model selection in fixed-n and sequential designs with a simulation study. In the example data set, the Bayesian framework provided evidence for the absence of a positive treatment effect on disease-free survival in patients with resected colon cancer. Furthermore, the Bayesian sequential analysis would have terminated the trial 13.3 months earlier than the standard frequentist analysis. In a simulation study with sequential designs, the Bayesian framework on average reached a decision in almost half the time required by the frequentist counterparts, while maintaining the same power, and an appropriate false-positive rate. Under model misspecification, the Bayesian framework resulted in higher false-negative rate compared to the frequentist counterparts, which resulted in a higher proportion of undecided trials. In fixed-n designs, the Bayesian framework showed slightly higher power, slightly elevated error rates, and lower bias and RMSE when estimating treatment effects in small samples. We have made the analytic approach readily available in RoBSA R package. The outlined Bayesian framework provides several benefits when applied to parametric survival analyses. It uses data more efficiently, is capable of greatly shortening the length of clinical trials, and provides a richer set of inferences.

READ FULL TEXT

page 9

page 17

research
06/06/2023

Bayesian meta-analysis for evaluating treatment effectiveness in biomarker subgroups using trials of mixed patient populations

During drug development, evidence can emerge to suggest a treatment is m...
research
10/24/2019

The use of registry data to extrapolate overall survival results from randomised controlled trials

Background: Pre-marketing authorisation estimates of survival are genera...
research
09/05/2023

Beyond the classical type I error: Bayesian metrics for Bayesian designs using informative priors

There is growing interest in Bayesian clinical trial designs with inform...
research
05/06/2019

Informed Bayesian Inference for the A/B Test

Booming in business and a staple analysis in medical trials, the A/B tes...
research
12/05/2022

Bayesian Reconciliation of Return Predictability

This article considers a stable vector autoregressive (VAR) model and in...
research
11/21/2019

Mixture survival models methodology: an application to cancer immunotherapy assessment in clinical trials

Progress in immunotherapy revolutionized the treatment landscape for adv...
research
09/16/2020

A Survival Mediation Model with Bayesian Model Averaging

Determining the extent to which a patient is benefiting from cancer ther...

Please sign up or login with your details

Forgot password? Click here to reset